All In Biotech

NDA 209241 · Neurocrine

Ingrezza

Valbenazine Tosylate · Oral

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Apr 11, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

33

9 Phase 3, 3 recruiting

FAERS reports

25,388

6,141 serious, 1,314 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. Anyone considering the use of INGREZZA or INGREZZA SPRINKLE must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are...

What it is approved for

From the label in effect Apr 17, 2026.

INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. ( 1 ) - chorea associated with Huntington’s disease. ( 1 )

Mechanism: The mechanism of action of valbenazine for the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 18, 2023 Supplement 26 · Efficacy OrphanLabelLetter
  • Apr 23, 2021 Supplement 20 · Efficacy LetterLabel
  • Apr 11, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
3 products under this application
  • INGREZZA · VALBENAZINE TOSYLATE EQ 80MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • INGREZZA · VALBENAZINE TOSYLATE EQ 60MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • INGREZZA · VALBENAZINE TOSYLATE EQ 40MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Valbenazine" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,780
  • somnolence2,504
  • fatigue1,699
  • tremor1,611
  • tardive dyskinesia1,537
  • fall1,149
  • dizziness968
  • death946
  • drooling926
  • dyskinesia904
  • therapeutic product effect decreased893
  • off label use697

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171,145
20183,935
20193,742
20204,036
20216,279
20221,723
20231,170
20241,124
20251,187
20261,047

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ingrezza (Valbenazine Tosylate)

2024 spending

$1.96B

Beneficiaries

32,171

254,899 claims

Per beneficiary

$60,819

$272.77 per unit

View as table
YearSpending
2020$788,822,963
2021$918,612,514
2022$1,266,279,975
2023$1,705,132,723
2024$1,956,616,319

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 35 on PubMed

Sponsor: Neurocrine Biosciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.